



RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED
PROCEDURE - EXAMINING GROUP 1642
PATENT

Attorney's Docket No. 5470-238

#16/C1
YC
8-1-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: MacDonald et al.

Serial No. 09/288,837

Filed: 8 April 1999

For: *METHODS AND MODIFIED CELLS FOR THE TREATMENT OF CANCER*

Group Art Unit: 1642

Examiner: B. Brumback

BOX AF
Commissioner for Patents
Washington, DC 20231

Date: July 26, 2001

RECEIVED

AUG 01 2001

Amendment after Final pursuant to 37 C.F.R. § 1.116

TECH CENTER 1600/2900

Sir:

Responsive to the Final Action dated March 30, 2001, it is respectfully requested that this application be reconsidered in view of the following amendments and remarks.

In the Claims.

Please cancel Claims 17-83 as drawn to non-elected inventions, without prejudice to the filing of divisional applications therefor.

Please cancel Claims 1-3, 5-8, 11, 12, 15, 16 and 94 without prejudice to the filing of a continuation application therefor.

Please cancel Claim 86-88 for the purposes of rewriting.

Please add the following new claims.

95. A composition comprising infectious Venezuelan Equine Encephalitis (VEE) particles in an immunogenically effective amount, wherein said VEE particles comprise one or more heterologous nucleotide sequences encoding a native cancer cell antigen, and further wherein said VEE particles comprise one or more attenuating mutations.

96. The composition of Claim 95, wherein said alphavirus particles are Venezuelan Equine Encephalitis virus replicon particles.

OK to enter
into
file
8/1/01
Sub 63